title: Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease.
abstract: Paraneoplastic cerebellar degeneration (PCD) is a rare neurological syndrome associated with lung cancer, breast adenocarcinoma,ovarian adenocarcinoma, and Hodgkin disease. It is rarely seen in pediatrics. We report a case of a 10-year-old boy with a 2-year prodrome that led to a diagnosis of PCD in association with stage IV Hodgkin disease. He received radiation and chemotherapy for his Hodgkin disease with resolution of his lymphoma. Based on promising data in adults on the efficacy of rituximab over other immuno suppressive agents in paraneoplastic disorders, he was treated with rituximab with marked improvement of the cerebellar syndrome.
authors.affiliation: Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Kee Kiat
authors.initials: KK
authors.lastname: Yeo
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Walter
authors.forename: Robin E
authors.initials: RE
authors.lastname: Miller
authors.forename: Josep
authors.initials: J
authors.lastname: Dalmau
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D020362:Paraneoplastic Cerebellar Degeneration / Q000188:drug therapy* / Q000209:etiology; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab